Introduction There are a paucity of real-world data examining effectiveness and safety of non-
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …

BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …

In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …

Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …

Background Novel oral anticoagulants are the cornerstone of therapy for non‐valvular atrial
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …

Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

Limited real-world data are available regarding the comparative safety of non-vitamin K
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Aims We aimed to evaluate bleeding risk in clinical practice in patients with atrial fibrillation
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …